Ketamine + Propofol for Traumatic Brain Injury
(Ketamine Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the safety of using ketamine (also known as Ketalar, Ketaset, and other names) with propofol to sedate patients with severe traumatic brain injuries in the ICU. Researchers aim to determine if this combination is better or as safe as the usual sedation treatments. Suitable participants have suffered a severe traumatic brain injury, are in the ICU, and require close brain pressure monitoring. As a Phase 4 trial, this research seeks to understand how this already FDA-approved and effective treatment can benefit more patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What is the safety track record for ketamine and propofol?
Research has shown that using ketamine with propofol for sedation in patients with traumatic brain injuries is generally safe. Studies have found that ketamine does not increase the risk of death or raise intracranial pressure, which indicates safety. Some studies even suggest that ketamine might help lower this pressure.
This trial is in Phase 4, meaning the FDA has already approved ketamine and propofol for other uses, confirming their safety. This phase typically evaluates safety and effectiveness in larger groups. Therefore, the treatment is likely to be well-tolerated, but this trial will provide more specific information for brain injury cases.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about using ketamine alongside propofol for traumatic brain injury because this combination could offer unique benefits compared to traditional options like fentanyl, morphine, or lorazepam. Unlike these standard treatments, which primarily focus on sedation and pain relief, ketamine has the added ability to potentially protect the brain by reducing inflammation and preventing further damage. Additionally, ketamine's fast-acting properties could lead to quicker improvements in patient outcomes. This combination aims to enhance recovery by targeting the brain's response to injury in a more comprehensive way.
What evidence suggests that this protocol is effective for traumatic brain injury?
In this trial, participants will receive either a combination of ketamine and propofol or standard of care analgosedation. Research has shown that "ketofol," a mix of ketamine and propofol, can improve blood flow and oxygen levels in the brain, which is vital for treating severe head injuries. Studies have found that ketamine helps lower intracranial pressure in these patients, preventing further brain damage. This combination is generally considered safe and may stabilize brain conditions more effectively than some other sedatives.15678
Who Is on the Research Team?
Bradley Dengler, MD
Principal Investigator
Uniformed Services University of the Health Sciences
Are You a Good Fit for This Trial?
This trial is for adults aged 18-65 with severe traumatic brain injury (TBI), indicated by a Glasgow Coma Scale score of 8 or less, who need intracranial pressure monitoring and are being treated in an ICU.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either ketamine with propofol or standard of care analgosedation for sedation in the ICU
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Ketamine
Ketamine is already approved in United States, European Union, Canada for the following indications:
- Anesthesia
- Treatment-resistant depression
- Anesthesia
- Treatment-resistant depression
- Treatment-resistant depression
- Treatment-resistant depression
- Treatment-resistant depression
Find a Clinic Near You
Who Is Running the Clinical Trial?
Henry M. Jackson Foundation for the Advancement of Military Medicine
Lead Sponsor
Uniformed Services University of the Health Sciences
Collaborator
Brooke Army Medical Center
Collaborator